All articles by Phillip Broadwith – Page 10
-
-
OpinionForged in righteous flames
Could the debate over pharma price-gouging have positive results for both patients and companies?
-
Business
Pfizer agrees potential $785m fraud settlement
Whistleblower case relates to claims of Wyeth overcharging for acid reflux drugs between 2001 and 2006
-
BusinessAkzoNobel to buy BASF’s industrial coatings
€475 million deal includes technology, products and sites in the UK and South Africa
-
Business
Lilly loses UK patent challenge
Allergan’s cancer drug generics do not infringe patents, say UK courts
-
Business
GSK fined for stalling antidepressant generics
UK Competition and Markets Authority deems pay-for-delay deal illegal and imposes £45m in fines
-
BusinessMedical devices consolidation continues
Abbott to buy Alere for $5.8bn to augment its point-of-care diagnostics business
-
Business
Merck & Co joins hepatitis C party
New drug adds new treatment options and increases competition in premium market
-
BusinessJ&J to cut 3000 jobs in medical devices unit
Cost-saving cuts will help ‘accelerate the pace of innovation’, company claims
-
OpinionThe kids aren’t alright
Making it more attractive for companies to develop paediatric drugs has the potential to improve everyone’s lives
-
Business
Fatal blast at US peroxide plant
One dead and three injured in an equipment explosion at PeroxyChem in Texas
-
Business
ThermoFisher will buy Affymetrix to expand genetic testing
Deal boosts Thermo’s position in growing genomics field as well as adding antibodies and assay technology
-
Business
GSK’s ViiV to buy HIV drugs from BMS
Deal hands over Bristol-Myers Squibb’s entire HIV pipeline as the company looks to quit virology research
-
-
-
Business
Perrigo nabs US rights to AZ Crohn’s drug
Irish generics maker evades Mylan takeover bid and expands gastroenterology portfolio
-
CareersThe classical singer
May Turner tells Phillip Broadwith how she balances topping the music charts with developing the latest generation of engine oils
-
Opinion
Toeing the advertising line
Companies have to tread a little carefully when it comes to advertising prescription drugs
-
BusinessBuilding better bottles
Catalytic Technologies wants to replace antimony catalysts in polyester production with safer, more active titanium
-
Business
AstraZeneca to buy ZS Pharma for ion-balance drugs
$2.7 billion deal anticipates regulatory success for drug candidate under review